Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination...

Related Keywords

Brazil ,United States ,Chicago ,Illinois ,Canada ,American ,Taylor Skott ,Vesna Tosic ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Pharmaceuticals Inc ,Nasdaq ,European Union ,Linkedin ,Velocimmune Technology ,American Society Of Clinical Oncology ,Drug Administration ,Regeneron Pharmaceuticals ,Exchange Commission ,Regeneron Genetics Center ,American Society ,Clinical Oncology ,Chief Scientific Officer ,Developmental Therapeutics ,Hematologic Malignancies ,Plasma Cell Dyscrasia ,Chronic Lymphocytic Leukemia ,Skin Cancers ,Lung Cancer ,Non Small Cell Metastatic ,Gynecologic Cancer ,Neck Cancer ,Nonproprietary Naming ,Biological Products Guidance ,Regeneron Genetics ,Looking Statements ,Product Candidates ,Markets ,